Mature central neurons lose their capacity for axon growth, but overexpression of growth-associated proteins restores this potential, which may support spinal cord regeneration. Injury to the ...

NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced positive topline results from the chronic cohort (1-10 years post injury) ...

Auxilium’s pivotal trial aims to enrol 80 patients who will receive its NeuroSpan Bridge device for nerve regeneration or a ...

The axolotl is renowned for its extensive ability to regenerate organs and body parts, including its spinal cord. Studies on ...

Auxilium Biotechnologies announced the 1st patient in its clinical trial of an investigational device designed to improve nerve regeneration.

UT Southwestern Medical Center scientists have identified a protein that appears to act as a master control switch for ...

An evolutionarily conserved mechanism for cAMP elicited axonal regeneration involves direct activation of the dual leucine zipper kinase DLK. Elife. 2016 Jun 7;5PubMed PMID: 27268300. Xiong X, Hao Y, ...

Spinal cord injury (SCI) is a devastating, debilitating, and life-altering condition that currently lacks a definitive cure or highly effective treatment ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Axon Enterprise saw healthy gains in both revenue and earnings, with particularly noteworthy gains in the software and services segment. A host of new products contributed to the company's overall ...

Axon Enterprise’s (NASDAQ:AXON) shares rose 5.7% in extended trading Wednesday after the maker of Tasers and other security equipment reported better-than-expected first-quarter results and ...